Pre-clinical data demonstrate robust
anti-tumor activity and a novel off-the-shelf approach for GPC3+
solid tumors
PHILADELPHIA, Nov. 5, 2024
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM)
("Carisma" or the "Company"), a clinical-stage biopharmaceutical
company focused on discovering and developing innovative
immunotherapies, today announced the upcoming presentation of new
pre-clinical data on its anti-GPC3 in
vivo chimeric antigen receptor macrophage and monocyte
(together, "CAR-M") therapy for the treatment of
hepatocellular carcinoma ("HCC"), developed in collaboration with
Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a
poster session at the Society for Immunotherapy of Cancer ("SITC")
Annual Meeting in Houston, Texas,
on November 8, 2024.
The abstract, titled "Pre-Clinical Efficacy of a Novel
Anti-GPC3 In Vivo CAR-M for Hepatocellular Carcinoma," presents
the first pre-clinical data on the development candidate targeting
Glypican-3 ("GPC3"), a tumor-associated antigen commonly expressed
in HCC. This novel off-the-shelf approach reprograms endogenous
myeloid cells in vivo using lipid nanoparticles ("LNP") to
deliver mRNA encoding CARs. The data show that this in vivo
CAR-M therapy has significant potential as a treatment for GPC3+
solid tumors, including HCC.
"Our data at SITC this year highlights the groundbreaking
potential of the in vivo CAR-M platform," said Steven Kelly, President and Chief Executive
Officer of Carisma. "The pre-clinical results demonstrate robust
anti-tumor activity and pave the way for an off-the-shelf therapy
for hard-to-treat cancers like hepatocellular carcinoma. This data
underscores the progress we've made, and we're eager to advance
this promising therapy into clinical development."
SITC Presentations Details:
Title: Pre-clinical efficacy of a novel anti-GPC3
in vivo CAR-M for hepatocellular carcinoma
Publication Number: 329
Session Date & Time: Friday, Nov.
8, 2024
Location: Exhibit Halls A B George R. Brown Convention
Center
Title: A Phase 1, First-in-Human study of autologous
monocytes engineered to express an anti-HER2 chimeric antigen
receptor (CAR) in participants with HER2 overexpressing solid
tumors
Publication Number: 659
Session Date & Time: Friday, Nov.
8, 2024
Location: Exhibit Halls A B George R. Brown Convention
Center
The poster presented at SITC 2024 will be available online
in the "Publications" section of Carisma's website at
https://carismatx.com/technology/publications/ following the start
of the poster session.
About Carisma Therapeutics
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated discovery, preclinical and clinical
development activities for Carisma's product candidates, the
potential safety, efficacy, benefits and addressable market
for Carisma's product candidates, and clinical trial results
for Carisma's product candidates. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," "continue," "will,"
"schedule," and "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on the Company's
current expectations and projections about future events and
various assumptions. Although Carisma believes that the
expectations reflected in such forward-looking statements are
reasonable, Carisma cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval is inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
Carisma's actual activities or results to differ significantly from
those expressed in any forward-looking statement, including risks
and uncertainties related to Carisma's ability to advance its
product candidates, the receipt and timing of potential regulatory
designations, approvals and commercialization of product
candidates, clinical trial sites and our ability to enroll eligible
patients, supply chain and manufacturing facilities, Carisma's
ability to maintain and recognize the benefits of certain
designations received by product candidates, the timing and results
of preclinical and clinical trials, Carisma's ability to fund
development activities and achieve development goals, Carisma's
ability to protect intellectual property, and other risks and
uncertainties described under the heading "Risk Factors" in
Carisma's Annual Report on Form 10-K for the year ended
December 31, 2023, its Quarterly
Reports on Form 10-Q and other documents that Carisma files from
time to time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and Carisma undertakes no obligation to revise or update
any forward-looking statements to reflect events or circumstances
after the date hereof, except as may be required by law.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-new-data-on-anti-gpc3-in-vivo-car-m-therapy-for-hepatocellular-carcinoma-at-sitc-2024-302295745.html
SOURCE Carisma Therapeutics Inc.